BioArctic AB confirmed the administration today, noting that the patient is the first in the country to access the therapy since it received European Union approval in April 2025. While the drug is designed to target the underlying causes of early-stage Alzheimer’s disease, its path to patients in Sweden has been complicated. In April 2026, the New Therapies Council, NT-rådet, issued a negative recommendation regarding the drug's inclusion in the publicly funded healthcare system.

Following that decision, Executive Health in Stockholm moved to provide the treatment independently. Gunilla Osswald, CEO of BioArctic, described the launch as a vital step in addressing the unmet needs of patients and their families. The therapy, which stems from research conducted by Professor Lars Lannfelt at Uppsala University, remains a focal point of a long-standing collaboration between BioArctic and the pharmaceutical company Eisai. The drug is currently indicated for adults diagnosed with mild cognitive impairment or mild dementia who meet specific genetic and pathological criteria.